The partnership will support the development of novel technologies in drug discovery, accelerate scientific talents across Canada, and advance Canada’s position as an international leader for healthcare innovation.
Catégorie : Network News
The partnership will significantly enrich GlycoNet’s and API’s capacities to support companies with innovations in glycomics.
GlycoNet researchers at Simon Fraser University are developing new molecules with the ultimate goal to improve the effectiveness of antitumor antibodies.
GlycoNet Investigator is developing a gel-based drug delivery system with a massive potential.
As the new year approaches, here is a look back at some of the most exciting advances from GlycoNet researchers in 2019.
GlycoNet Investigators are looking into using carbohydrate-binding proteins to help battle fungal pathogens.
GlycoNet scientists solved the structure of an enzyme that could help burn victims and prevent deaths from different kinds of infections.
GlycoNet Investigator sets the stage for new therapeutic strategies for Alzheimer’s disease.
GlycoNet researchers discovered a molecule against Methicillin-resistant (MRSA) bacteria.
GlycoNet scientists identified an enzyme possibly related to bacterial virulence and antibiotic resistance.